PTH1R-CaSR Cross Talk: New Treatment Options for Breast Cancer Osteolytic Bone Metastases
Metastatic breast cancer (BrCa) is currently incurable despite great improvements in treatment of primary BrCa. The incidence of skeletal metastases in advanced BrCa occurs up to 70%. Recent findings have established that the distribution of BrCa metastases to the skeleton is not a random process bu...
Saved in:
Main Authors: | Yanmei Yang, Bin Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2018/7120979 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction
by: Rui Liu, et al.
Published: (2025-01-01) -
CHD7 Regulates Osteogenic Differentiation of Human Dental Follicle Cells via PTH1R Signaling
by: Caojie Liu, et al.
Published: (2020-01-01) -
OBTAINING AND TESTING OF MG-CA-SR BIODEGRADABLE MATERIALS USED IN MEDICINE
by: Kamel Earar, et al.
Published: (2024-12-01) -
Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
by: Dirk Hose, et al.
Published: (2024-12-01) -
Correction: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
by: Dirk Hose, et al.
Published: (2025-01-01)